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The antineoplastic compound aplidine, a new marine-derived depsipeptide, has shown preclinical activity in vitro on haematological
and solid tumour cell lines. It is currently in early phase clinical trials. The exact mechanism of action of this anticancer agent still needs
to be clarified. We have previously reported that aplidine blocks the secretion of the angiogenic factor vascular endothelial growth
factor (VEGF) by the human leukaemia cells MOLT-4, suggesting a possible effect on tumour angiogenesis. This study was designed to
investigate the antiangiogenic effect of aplidine. In vivo, in the chick embryo allantoic membrane (CAM) assay, aplidine inhibited
spontaneous angiogenesis, angiogenesis elicited by exogenous VEGF and FGF-2, and induced by VEGF overexpressing 1A9 ovarian
carcinoma cells. In vitro, at concentrations achievable in the plasma of patients, aplidine inhibited endothelial cell functions related to
angiogenesis. It affected VEGF- and FGF-2-induced endothelial cell proliferation, inhibited cell migration and invasiveness assessed in
the Boyden chamber and blocked the production of matrix metalloproteinases (MMP-2 and MMP-9) by endothelial cells. Finally,
aplidine prevented the formation of capillary-like structures by endothelial cells on Matrigel. These findings indicate that aplidine has
antiangiogenic activity in vivo and inhibits endothelial cell functional responses to angiogenic stimuli in vitro. This effect might contribute
to the antineoplastic activity of aplidine.
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Aplidine, dehydrodidemnin B, is a marine-derived antitumour
agent isolated from the Mediterranean tunicate Aplidium albicans
(Sakai et al, 1996; da Rocha et al, 2001; Jimeno, 2002; Vera and
Joullie, 2002). It is a cyclic depsipeptide, structurally related to
other naturally occurring didemnins, such as didemnin B.
Aplidine was at first selected for its enhanced cytotoxicity
against different tumour cells lines and lower myelotoxicity
relative to didemnin B (Geldof et al, 1999; Albella et al, 2002). In
vitro, aplidine inhibited tumour cell proliferation with an IC50 in
the nanomolar/subnanomolar range, with complete inhibition
achieved at 10nM (Lobo et al, 1997; Erba et al, 2002; Erba et al,
2003). Short-term exposure to aplidine rapidly caused apoptosis of
tumour cells (Erba et al, 2002; Gajate et al, 2003) and prevented the
formation of colonies by explanted tumour cells (Depenbrock et al,
1998). In xenograft models, aplidine showed activity against
different tumour types (Albella et al, 2002). Results from early
phase clinical trials have confirmed the reduced myelotoxicity of
aplidine relative to didemnin B, and have shown activity against
certain tumour types such as medullary thyroid carcinoma, renal-
cell carcinoma, melanoma and tumours of neuroendocrine origin
(reviewed in Schwartsmann et al, 2001).
The molecular mechanism of action of aplidine still remains to
be clarified, as different activities of the compound have been
described that might potentially contribute to its antitumour
activity (Sakai et al, 1996; Vera and Joullie, 2002). The
antiproliferative effect of aplidine on cancer cells has been
associated to perturbation in the cell cycle, since aplidine, at low
concentrations, induces blockade of the cell cycle at G1 and at G2
(Geldof et al, 1999; Erba et al, 2002). Didemnins also block protein
synthesis (Crews et al, 1994), inhibit ornithine decarboxylase, a
regulator of intracellular polyamine levels (Urdiales et al, 1996;
Gomez-Fabre et al, 1997; Erba et al, 2002) and bind to and inhibit
the activity of the palmitoyil protein thioesterase, involved in
signal transduction pathways associated to cell proliferation
(Crews et al, 1996). However, the relevance of these activities in
determining the antineoplastic activity of the compound is still
debated.
We have previously reported that aplidine inhibited the
secretion of vascular endothelial growth factor (VEGF) by the
human leukaemia MOLT-4 cells, leading to blockage of the VEGF/
VEGFR-1 autocrine loop that regulated MOLT-4 cell proliferation
(Fusetti et al, 2000; Marchini et al, 2002; Broggini et al, 2003).
Vascular endothelial growth factor is one of the major stimulators
of angiogenesis, the formation of new blood vessels during
physiological and pathological conditions (Folkman, 1995; Carme-
liet and Jain, 2000). Angiogenesis is crucial in the progression of
tumours, since the growth of the tumour mass and the process of
metastasis depend on the existence of a functional blood supply
system (Folkman, 1995; Carmeliet and Jain, 2000). Therefore, the
inhibitory activity of aplidine on VEGF production suggested that
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sthe compound might exert an antiangiogenic effect by interfering
with VEGF-mediated responses. This, in turn, might represent an
additional mechanism of the antineoplastic activity of aplidine.
This study was designed to further investigate the antiangiogenic
activity of aplidine, in in vitro and in vivo models of angiogenesis.
MATERIALS AND METHODS
Aplidine
Aplidine (provided by PhamaMar, Madrid, Spain) was dissolved in
DMSO or absolute ethanol (1000  stock solution) and further
diluted in the test medium immediately before the assay. In all the
in vitro experiments, control cells received the same volume of
DMSO (‘vehicle’). At the used dilution (at least 1:1000), DMSO
had no effect on endothelial cell motility and proliferation. Similar
results were obtained when aplidine was dissolved in DMSO or in
absolute ethanol.
Cells
Human umbilical vein endothelial cells (HUVECs) were isolated
from umbilical cord veins and grown on 1% gelatin-coated flasks
in M199 supplemented with 10% foetal calf serum (FCS), 10%
newborn calf serum, 20mmoll
 1 HEPES, 6Uml
 1 heparin,
2mmoll
 1 glutamine, 50mgml
 1 endothelial cell growth factor
(crude extract from bovine brain), penicillin and streptomycin.
Cells were used between the third and fifth passage.
The human ovarian carcinoma 1A9 cells and its VEGF-
overexpressing clone 1A9-VS4 were cultured in RPMI 10% FCS.
1A9-VS4, obtained by transfection of 1A9 cells with the human
VEGF cDNA, was found to express four-fold higher levels of VEGF
compared to parental 1A9 cells (manuscript in preparation).
Tumour cells (10 10
6) were injected subcutaneously in nude
mice. Growing tumours were collected and fragments were grafted
onto the chick embryo allantoic membrane (CAM).
Human proximal tubular epithelial cells HK-2, from the
American Type Culture Collection (Rockville, MD, USA), were
cultured as described (Morigi et al, 2002).
Angiogenesis assay (chorioallantoic membrane assay)
Fertilised White Leghorn chicken eggs (10 per group) were
incubated at 371C at constant humidity. On day 3 of incubation,
a square window was opened in the egg shell after the removal of
2–3ml of albumen so as to detach the developing CAM from the
shell. The window was sealed with a glass and the eggs were
returned to the incubator. On day 8, 1mm
3 sterilised gelatin
sponges (Gelfoam Upjohn, Kalamazoo, MI, USA) were placed on
the top of the growing CAM, according to the method of Ribatti
et al (1997). Then, the sponges were loaded with: (a) 1mlo f
phosphate-buffered saline (PBS) containing different concentra-
tions of aplidine (1, 5, 10 and 20nM); (b) 1ml of PBS or 1ml of PBS
containing 500mg of recombinant human VEGF165 or FGF-2 (R &
D Systems, Abingdon, UK) as negative and positive controls,
respectively; and (c) 1ml of PBS containing 500mg of recombinant
human VEGF165 or FGF-2 and 10nM of aplidine.
In a second set of experiments, 1mm
3 bioptic fragments
obtained from xenografts derived from 1A9 and 1A9-VS4 tumours
(see above) were grafted onto the CAM on day 8. Tumour
fragments were gently placed onto the CAM surface and care was
taken to avoid injuring major blood vessels, as described
(Knighton et al, 1977). At different times after grafting (4, 28, 52
and 72h), embryos were treated with PBS or with 10nM aplidine
pipetted directly onto the implants.
CAMs were examined daily until day 12 and photographed in
ovo with a stereomicroscope equipped with a Camera System MC
63 (Zeiss, Oberkochen, Germany). On day 12, blood vessels
entering the sponges or the implants within the focal plane of the
CAM were counted by two observers in a double-blind manner at
 50 magnification. The mean values7standard deviation (s.d.)
for vessel counts were determined for each analysis.
Endothelial cell proliferation assay
To assess proliferation (Belotti et al, 1996; Taraboletti et al, 2002),
HUVECs (4 10
3 cellswell
 1) were plated in a 96-well plate in a
medium containing 5% serum. After 24h, FGF-2 or VEGF
(10ngml
 1) were added, together with the compound. Vehicle
or aplidine (0.02–20nM) were incubated for 1, 24 or 72h. After
washing, cells were incubated in the medium supplemented with
FGF-2 or VEGF for a total 3 days. Cells were fixed and stained with
0.5% crystal violet in 20% methanol, rinsed and air-dried. The
stain was eluted with ethanol:0.1 M sodium citrate solution (1:1)
and absorbance at 540nm was measured with a Multiscan MC
Titertek (Flow Laboratories, Milan, Italy). Data are expressed as
the percentage of control proliferation (vehicle-treated cells) and
as the IC50 (drug concentration causing 50% inhibition).
Endothelial cell motility and invasion assays
Motility and invasiveness were assayed using modified Boyden
chambers, with 8mm pore size, polycarbonate PVP-free Nucleo-
pore filters (Belotti et al, 1996; Taraboletti et al, 2002). NIH-3T3
supernatant (a rich source of motility stimuli) was used as the
attractant and was added to the lower compartment of the
chamber. For chemotaxis, filters were coated with 0.1% gelatin. For
invasion, filters were coated with a thick layer of the reconstituted
basement membrane Matrigel (Beckton Dickinson, Bedford, MA,
USA; 0.5mgml
 1) that cells have to degrade in order to reach and
migrate through the filter. In this assay, invasion is prevented by
inhibitors of matrix-degrading proteases, which do not affect
chemotaxis (Taraboletti et al, 1995), therefore proving the true
functional distinction between the assays of invasion and
chemotaxis. Human umbilical vein endothelial cells were detached
and treated with vehicle or aplidine (0.03–10nM) for 1h at 371Ci n
DMEM–0.1% BSA. Cells were then washed in DMEM–0.1% BSA,
resuspended in the same medium at the concentration of
0.75 10
6ml
 1 and added to the upper compartment of the
chamber. After 4h (motility) or 6h (invasion), the filters were
stained with Diff-Quik (Marz-Dade, Dudingen, Switzerland) and
the migrated cells in 10 high-power fields were counted. Data are
expressed as the percentage of control migration (vehicle-treated
cells) and as IC50 (drug concentration causing 50% inhibition).
Production of matrix metalloproteinases (MMPs)
Subconfluent HUVECs were treated with vehicle or aplidine (1.25–
20nM) for 1h, washed and incubated in serum-free DMEM for
16h, with or without phorbol 12-myristate 13-acetate (PMA,
100ngml
 1). The supernatants were then collected, the remaining
cells were counted and the presence of MMP-2 and MMP-9 in the
serum-free supernatants was analysed by zymography (Belotti et al,
1996). Samples (volume adjusted according to the cell number), in
70mM Tris-HCl pH 6.8, 10% glycerol, 2% SDS and 0.01%
bromophenol blue, were applied to SDS–polyacrylamide (8%)
gels copolymerised with 1mgml
 1 gelatin. After electrophoresis,
gels were washed three times for 20min with 2.5% Triton X-100 at
room temperature and incubated overnight in 50mM Tris-HCI, pH
7.5, 5mM CaCl2, 150mM NaCl and 0.02% Brij-35 at 371C. Gels were
then stained with 0.5% Coomassie blue in 25% methanol and 10%
acetic acid, and destained in the same solution without Coomassie
blue. Supernatant of the human melanoma cells WM983A was used
as a reference standard for pro-MMP-9 and pro-MMP-2.
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The ability of HUVEC to form capillary-like structures on a 3D
layer of basement membrane (Matrigel) was tested (Belotti et al,
1996; Taraboletti et al, 2002). Ice-cold Matrigel (10mgml
 1,6 0ml)
was layered in a 96-well plate and incubated at 371C for 30min to
allow polymerisation. Human umbilical vein endothelial cells were
treated with vehicle or aplidine (0.03–10nM) for 1h before the
assay and then plated (2 10
4well
 1) onto the Matrigel layer in the
culture medium. Images were taken 24h later, when cords were
formed. Cord formation was quantified by measuring the total
length of formed cords (Image Pro-Plus 4.5, Media Cybernetics,
Silver Spring, MD, USA).
RESULTS
Effects of aplidine on the vascularisation of the chick CAM
The antiangiogenic activity of aplidine was investigated in the
chick CAM assay, in vivo, a useful model to investigate the effect of
compounds on both basal angiogenesis and angiogenesis induced
by an exogenous stimulus (Ribatti et al, 2001). Aplidine, added to
the CAM, affected the basal growth of vessels, inhibiting the
number of blood vessels in 80% of the treated embryos (Figure 1).
Aplidine also affected angiogenesis induced by exogenous
angiogenic factors added to the CAMs. Vascular endothelial
growth factor or FGF-2 induced the growth of numerous allantoic
vessels converging like spokes toward the sponge (Figure 2A).
Aplidine (10nM) significantly reduced the angiogenic response
induced by VEGF and, at a lower extent, by FGF-2 (Figures 1 and
2B).
We next investigated whether aplidine also inhibited tumour
angiogenesis induced in the CAM by tumours. The human ovarian
carcinoma 1A9 and its VEGF overexpressing clone 1A9-VS4 were
injected subcutaneously in nude mice. Grown tumours were
collected, and fresh fragments were grafted onto the CAM, on day
8. Tumour specimens induced a strong angiogenic response,
higher in 1A9-VS4 than in 1A9 grafts (number of vessels on day 12
was 3075 and 1874, respectively, n¼10) (Figure 3A). The
addition of aplidine caused a significant (Pp0.001) reduction in
the angiogenic response induced by the tumour specimens
(number of vessels was 2074 and 1173 for 1A9-VS4 and 1A9,
respectively, Figure 3B).
These findings indicate that aplidine prevented angiogenesis in
vivo, affecting both physiologic, spontaneous angiogenesis of the
embryo, angiogenesis induced by exogenous stimuli (VEGF and
FGF-2) and tumour angiogenesis. Interestingly, the normal
structure of the other components of the CAM, such as the
chorionic and allantoic epithelia and the fibroblasts, was not
affected, suggesting a selective effect of aplidine on the vascular
structures.
In vitro effects of aplidine on endothelial cell functions
The in vivo results pointed to a direct inhibitory effect of aplidine
on endothelial cells. We therefore investigated, in vitro, whether
aplidine could affect endothelial cell functions relevant to
angiogenesis. In particular, the process of angiogenesis requires
endothelial cell proliferation, motility, extracellular matrix degra-
dation and invasion through the underlying basement membrane
and interstitial matrix and, finally, spatial organisation to form a
network of new vessels.
Aplidine inhibited the proliferation of endothelial cells
(Figure 4). The antiproliferative effect of aplidine was observed
when proliferation was stimulated by both VEGF and FGF-2. Some
inhibitory effect was observed after 1h exposure to the compound,
with IC50 of 8.1 and 5.7nM for VEGF and FGF-2, respectively.
Exposure to aplidine for longer times (24–72h) increased the
cytotoxic effect of the compound (Figure 4). Confluent, quiescent
endothelial cells were much less sensitive to the cytotoxic effect of
aplidine than actively proliferating cells (IC50 was more than 10
times higher), even at long exposure times (72h, not shown). In
contrast, the same concentrations of aplidine that prevented
endothelial cell proliferation were not active on the proliferation of
the human proximal tubular epithelial cells HK-2 (Figure 4C).
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Figure 1 Effect of aplidine on angiogenesis in the CAM. Sponges loaded
with PBS (spontaneous, basal angiogenesis), VEGF or FGF-2 and aplidine at
the indicated concentration were implanted on CAMs on day 8 of
incubation. On day 12, blood vessels entering the sponges or the implants
within the focal plane of the CAM were counted by two observers in a
double-blind manner at  50 magnification. Results are expressed as the
percentage of control response (mean and s.d., n¼10). Vascular
endothelial growth factor and FGF-2 induced a 4.7- and 4.2-fold increase
in angiogenic response (3877 and 3474 vessels, respectively) compared
to control (872 vessels).
A
B
Figure 2 CAM of a 12-day old chick embryo incubated for 4 days with a
gelatin sponge loaded with VEGF alone (A) or with 10nM aplidine (B).
Note in (A) numerous blood vessels converging towards the sponge,
whereas in (B) there are very few vessels around the sponge or converging
toward it. Original magnification,  50.
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assayed in the Boyden chamber, using supernatant of NIH-3T3
cells as the attractant. Pretreatment with aplidine for 1h resulted in
a dose-dependent inhibition of cell migration, with an IC50 of
5.5nM for chemotaxis and 0.9nM for invasiveness (Figure 5). The
same results were obtained when aplidine was added to the lower
compartment of the chemotaxis chamber (not shown). Aplidine
also inhibited the motility and invasive response of endothelial
cells to VEGF and FGF-2 (for chemotaxis, IC50 was 9.5 and 11.6nM;
for chemoinvasion, IC50 was 1.8 and 0.5nM for VEGF and FGF-2,
respectively).
Since the process of invasion requires enzymatic digestion of the
matrix, we investigated whether aplidine affected the production of
matrix-degrading metalloproteinases by endothelial cells. Human
umbilical vein endothelial cells were exposed to aplidine (2.5–
10nM) for 1h, washed and the serum-free conditioned medium,
collected 20h later, was tested for the presence of MMP-2 and
MMP-9 by zymography. Aplidine dose dependently prevented the
production of MMP-2 in nonstimulated HUVECs (Figure 6).
Treatment of HUVECs with PMA stimulated the production of
MMP-9 and the activation of MMP-2. In aplidine-treated cells,
even in the presence of PMA, pro-MMP-9 and activated MMP-2
were undetectable, and pro-MMP-2 was strongly reduced com-
pared to vehicle-treated cells (Figure 6). Since we have previously
reported that aplidine was able to affect the secretion of VEGF
(Broggini et al, 2003), we also checked whether MMP secretion was
affected by the compound. For this purpose, we analysed the levels
of intracellular and secreted MMP-2 at different times (1, 3, 6, and
16h) after aplidine treatment. Aplidine decreased total MMP
levels, but did not change the rate of MMP secretion (data not
shown), suggesting that reduction in MMP production by aplidine
does not occur through perturbation of the MMP secretion
process.
We finally evaluated the effect of aplidine on the alignment of
endothelial cells in capillary-like structures. Endothelial cells were
plated onto a thick layer of Matrigel where they rapidly align
forming cords. The presence of aplidine in the assay, at
concentrations X1n M, caused a concentration-dependent inhibi-
tion of cord formation (Figure 7). At the concentration of 10nM
aplidine caused 69% reduction in the total length of formed cords.
DISCUSSION
This study shows that aplidine, a second-generation didemnin,
exerts an antiangiogenic effect in vivo in the CAM model and
affects endothelial cell functions relevant for the angiogenic
process in vitro. The antiangiogenic effect of aplidine was observed
at concentrations achievable in plasma following the administra-
tion of the drug to patients (Armand et al, 2002).
A
B
Figure 3 Macroscopic observations on day 12 of the effect of aplidine
on tumour xenograft-induced CAM vascularisation. Fragments of the same
bioptic specimen from 1A9-VS4 tumours were grafted onto the CAM on
day 8 in the absence (A) or presence of aplidine (B), and incubated for 4
days. A reduction in the number of blood vessels invading the graft is
observed in aplidine-treated biopsy (B) compared to control (A). Original
magnification,  50.
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Figure 4 Effect of aplidine on endothelial cell proliferative response to
10ngml
 1 FGF-2 (A) or VEGF (B), or on the proliferation of human
proximal tubular epithelial cells HK-2 (C). Cells were exposed to the
indicated concentration of the compound for 1 (diamonds), 24 (triangles)
or 72h (circles). Data, mean and s.d. of triplicate, are the percentage of
control proliferation (vehicle alone).
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from our previous finding showed that the compound inhibited
the production of VEGF by tumour cells (Broggini et al, 2003),
therefore indicating a possible effect of aplidine in reducing
tumour angiogenic potential. The present study confirms that
aplidine does exert a potent antiangiogenic activity, but it shows
that in our models this activity is due to a direct effect on
endothelial cells rather than interference with the production of
angiogenic factors. Different evidences support this conclusion. (1)
In the CAM assay, aplidine not only inhibited physiological
angiogenesis but also angiogenesis induced by exogenous FGF-2
and VEGF, suggesting that aplidine is a general inhibitor of
angiogenesis, even when the direct addition of exogenous stimuli
rule out a possible effect on angiogenic factor production. (2) In
vitro aplidine did not affect the production of VEGF by 1A9 and
1A9-VS4 tumour cells (data not shown), indicating that the
antiangiogenic effect observed in vivo in the model of tumour
grafts was not due to a reduced production of VEGF by the tumour
cells. (3) Aplidine directly affected endothelial cell functions
relevant to angiogenesis in vitro. Altogether, these findings
indicate that aplidine is a general inhibitor of angiogenesis that
directly acts on endothelial cells.
Our finding that aplidine affected VEGF secretion in the
leukaemic MOLT-4 cells, but not in 1A9 ovarian carcinoma cells,
is in keeping with the recent evidence that aplidine is able to block
the secretion of VEGF in some tumour cell lines but not in others
(Erba et al, 2003), suggesting that the compound could exert its
cytotoxic activity through different mechanisms in different
tumour types.
Angiogenesis is a multistep process, in which quiescent
endothelial cells are stimulated by angiogenic factors to proliferate,
migrate, invade the underlying matrix, form capillary-like tubular
structures and, finally, organise a network of mature, functional
blood vessels. Our findings that aplidine blocked endothelial cell
proliferation, migration, invasion and cord formation in vitro
suggest that the compound acts at multiple levels of the angiogenic
cascade, and might explain its potent activity in vivo.
The molecular mechanisms of the antiangiogenic activity of
aplidine still need to be defined. Different activities of aplidine
have been described that might potentially contribute to its
antiangiogenic effect, including effects on cell cycle/proliferation/
apoptosis, as well as on protein synthesis and secretion. Aplidine
inhibits endothelial cell proliferation, with an IC50 similar to that
observed for tumour cells. Other studies reported that concentra-
tions of aplidine that completely inhibited colony formation by
cancer cells were almost ineffective on bone marrow and cord
blood haematopoietic progenitor cells, nonstimulated lymphocytes
and hepatocytes (Sakai et al, 1996; Gomez et al, 2001; Albella et al,
2002; Erba et al, 2003; Gajate et al, 2003). In agreement, we found
that the concentrations of aplidine that affected endothelial cell
proliferation had no relevant antiproliferative effect on epithelial
cells. Therefore, at least some normal cell types are less sensitive
than cancer cells to the antiproliferative and proapoptotic effects of
aplidine. Our finding that endothelial cells are very sensitive to the
compound therefore suggests that proliferating, angiogenic
endothelial cell might be affected by aplidine in conditions in
which other normal cell types are spared. This is further supported
by the observation that aplidine did not interfere with the normal
structure of the other components of the CAM, such as chorionic
and allantoic epithelia and the fibroblasts. Moreover, our finding
that aplidine is active on VEGF- and FGF-stimulated endothelial
cells suggests that the compound might indeed affect the
endothelium of tumour vessels, exposed to an environment rich
in angiogenic and proliferating stimuli.
Several cytotoxic antineoplastic drugs are known to affect
endothelial cell functions and to affect angiogenesis (Belotti et al,
1996; Hanahan et al, 2000; Klement et al, 2000; Kerbel and
Folkman, 2002; Taraboletti et al, 2002). However, some of them
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Figure 5 Effect of aplidine on endothelial cell motility and invasiveness.
Human umbilical vein endothelial cells were treated with the indicated
concentration of aplidine for 1h and washed before the assay. Motility (A)
and invasion (B) were assessed in the Boyden chamber, using supernatant
of NIH-3T3 cells as the attractant. Data are the number of migrated cells in
10 high-power fields (dotted line¼baseline motility).
Aplidine (nM)
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Vehicle
Aplidine (nM)
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w/o PMA
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MMP-2
MMP-9
MMP-2
Figure 6 Effect of aplidine on the production of MMP-2 and MMP-9 by
endothelial cells. Human umbilical vein endothelial cells were treated with
vehicle or with the indicated concentration of aplidine for 1h, washed and
incubated for 16h in serum-free medium containing or not containing PMA
(100ngml
 1). The supernatant was then analysed by zymography.
Gelatinolytic bands corresponding to pro-MMP-9, pro- and activated
MMP-2 are indicated.
Control 0.3 1 3 10
Aplidine (nM)
Figure 7 Effect of aplidine on the formation of capillary-like structures by
endothelial cells. Human umbilical vein endothelial cells were treated or not
with the indicated concentration of aplidine for 1h, washed and plated
onto a thick layer of Matrigel (10mgml
 1) where untreated cells rapidly
align, forming a network of cords. Images were taken 24h after plating
( 40).
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concentrations required to affect endothelial cells exceed those
effective on cancer cells (Schirner, 2000; Miller et al, 2001). In this
respect, our findings suggest that endothelial cells and cancer cells
might be concomitantly affected by the same concentrations of
aplidine, suggesting that the antiangiogenic effect might indeed
occur in tumours and contribute to the final antineoplastic
activity.
Didemnins also inhibit protein synthesis, by binding the
translation elongation factor EF1-alpha (Crews et al, 1994).
Moreover, aplidine prevents the secretion of VEGF (Broggini
et al, 2003). It was therefore possible that these activities on
protein synthesis and secretion could contribute to the antiangio-
genic effect of the compound. Indeed we found that aplidine
reduced the production, but not the secretion, of MMP-2 and
MMP-9, two key enzymes in angiogenesis, supporting the
hypothesis that inhibition of protein synthesis, although not
secretion, might contribute to this activity. The effect of aplidine
on MMPs might explain its higher potency (lower IC50) observed
on invasiveness than on motility.
Aplidine, as other didemnins, has immunosuppressive activity
(Sakai et al, 1996; Vera and Joullie, 2002). The relationship
between the immune system and angiogenesis, particularly in the
malignant disease, is well documented, and several immunomo-
dulatory agents are known to affect angiogenesis (D’Amato et al,
1994; Turk et al, 1998; O’Byrne et al, 2000; Guba et al, 2002; Raje
and Anderson, 2002). The relevance of this aspect in determining
the antiangiogenic activity of aplidine is not clear. However, it is
worth noting the striking similarity among aplidine and the
apparently unrelated immunosuppressive agent rapamycin (Guba
et al, 2002). Both compounds affect angiogenesis through a double
mechanism of action: reduction in VEGF production by tumour
cells and concomitant direct inhibitory effect on endothelial cell
functions (Guba et al, 2002). Further investigations are needed to
investigate whether this functional similarity implies a common
molecular mechanism of action of the two agents.
In conclusion, this study indicates that aplidine has antiangio-
genic activity in in vivo and in vitro models, at clinically relevant
concentrations. Besides the reported activity on VEGF production
(Broggini et al, 2003), the present study indicates an additional
mechanism of action, through direct effect on endothelial cell
functional response to angiogenic stimuli. Further studies are
needed to further define the relative effect of aplidine on the two
compartments (tumour and endothelial cells) and to identify
optimal schedule and doses, to better exploit its multifaceted
antineoplastic potential.
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